Consequently, anti-PDGFR-β therapies have been suggested in cancers where PDGFR-β-positive ECs are present [40].These observations indicated that the combined application of PDGFR-β and PDGF-BB might increase the risk of tumor progression. The gene discussed is PDGFRB; the disease is neoplasm.